Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
Adam Ioannou,1 Irene Tsappa,2 Sofia Metaxa,3 Constantinos G Missouris2,3 1Cardiology Department, Royal Free NHS Foundation Trust, London, UK; 2Cardiology Department, Medical School, University of Cyprus, Nicosia, Cyprus; 3Cardiology Department, Frimley Health NHS Foundation Trust, London, UK Abstrac...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-11-01
|
| Series: | Patient Related Outcome Measures |
| Subjects: | |
| Online Access: | https://www.dovepress.com/non-valvular-atrial-fibrillation-impact-of-apixaban-on-patient-outcome-peer-reviewed-article-PROM |
| _version_ | 1817979036644671488 |
|---|---|
| author | Ioannou A Tsappa I Metaxa S Missouris CG |
| author_facet | Ioannou A Tsappa I Metaxa S Missouris CG |
| author_sort | Ioannou A |
| collection | DOAJ |
| description | Adam Ioannou,1 Irene Tsappa,2 Sofia Metaxa,3 Constantinos G Missouris2,3 1Cardiology Department, Royal Free NHS Foundation Trust, London, UK; 2Cardiology Department, Medical School, University of Cyprus, Nicosia, Cyprus; 3Cardiology Department, Frimley Health NHS Foundation Trust, London, UK Abstract: Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacological agent worldwide. In this review, we will provide an overview of the pivotal trials in the development of apixaban, while also critically evaluating the new emerging real-world data, and discussing the effectiveness, safety, economic viability and future prospects of apixaban and how it impacts on patient outcomes in those with non-valvular atrial fibrillation. Keywords: apixaban, atrial fibrillation, warfarin, stroke, bleeding |
| first_indexed | 2024-04-13T22:37:42Z |
| format | Article |
| id | doaj.art-05bfe60456d64b0e81f56ba29dc818be |
| institution | Directory Open Access Journal |
| issn | 1179-271X |
| language | English |
| last_indexed | 2024-04-13T22:37:42Z |
| publishDate | 2017-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Related Outcome Measures |
| spelling | doaj.art-05bfe60456d64b0e81f56ba29dc818be2022-12-22T02:26:43ZengDove Medical PressPatient Related Outcome Measures1179-271X2017-11-01Volume 812113135442Non-valvular atrial fibrillation: impact of apixaban on patient outcomesIoannou ATsappa IMetaxa SMissouris CGAdam Ioannou,1 Irene Tsappa,2 Sofia Metaxa,3 Constantinos G Missouris2,3 1Cardiology Department, Royal Free NHS Foundation Trust, London, UK; 2Cardiology Department, Medical School, University of Cyprus, Nicosia, Cyprus; 3Cardiology Department, Frimley Health NHS Foundation Trust, London, UK Abstract: Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacological agent worldwide. In this review, we will provide an overview of the pivotal trials in the development of apixaban, while also critically evaluating the new emerging real-world data, and discussing the effectiveness, safety, economic viability and future prospects of apixaban and how it impacts on patient outcomes in those with non-valvular atrial fibrillation. Keywords: apixaban, atrial fibrillation, warfarin, stroke, bleedinghttps://www.dovepress.com/non-valvular-atrial-fibrillation-impact-of-apixaban-on-patient-outcome-peer-reviewed-article-PROMApixabanAtrial FibrillationWarfarinStroke |
| spellingShingle | Ioannou A Tsappa I Metaxa S Missouris CG Non-valvular atrial fibrillation: impact of apixaban on patient outcomes Patient Related Outcome Measures Apixaban Atrial Fibrillation Warfarin Stroke |
| title | Non-valvular atrial fibrillation: impact of apixaban on patient outcomes |
| title_full | Non-valvular atrial fibrillation: impact of apixaban on patient outcomes |
| title_fullStr | Non-valvular atrial fibrillation: impact of apixaban on patient outcomes |
| title_full_unstemmed | Non-valvular atrial fibrillation: impact of apixaban on patient outcomes |
| title_short | Non-valvular atrial fibrillation: impact of apixaban on patient outcomes |
| title_sort | non valvular atrial fibrillation impact of apixaban on patient outcomes |
| topic | Apixaban Atrial Fibrillation Warfarin Stroke |
| url | https://www.dovepress.com/non-valvular-atrial-fibrillation-impact-of-apixaban-on-patient-outcome-peer-reviewed-article-PROM |
| work_keys_str_mv | AT ioannoua nonvalvularatrialfibrillationimpactofapixabanonpatientoutcomes AT tsappai nonvalvularatrialfibrillationimpactofapixabanonpatientoutcomes AT metaxas nonvalvularatrialfibrillationimpactofapixabanonpatientoutcomes AT missouriscg nonvalvularatrialfibrillationimpactofapixabanonpatientoutcomes |